Although it was only conducted under the conditions of phase 2 studies in East Asia, trastuzumab deruxtecan was the first HER2-targeted drug to show a survival benefit against gastric cancer since trastuzumab in the ToGA study. The gene discussed is ERBB2; the disease is gastric cancer.